Context Therapeutics Inc. - Common Stock (CNTX)
CUSIP: 21077P108
Q3 2023 13F Holders as of 30 Sep 2023
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 91,741,639
- Total 13F shares
- 2,578,656
- Share change
- +339,490
- Total reported value
- $3,893,359
- Price per share
- $1.51
- Number of holders
- 23
- Value change
- +$507,040
- Number of buys
- 10
- Number of sells
- 3
Quarterly Holders Quick Answers
What is CUSIP 21077P108?
CUSIP 21077P108 identifies CNTX - Context Therapeutics Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 21077P108:
Top shareholders of CNTX - Context Therapeutics Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Ally Bridge Group (NY) LLC |
13F
|
Company |
0.71%
|
653,396
|
$1,045,434 | — | 30 Jun 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.63%
|
574,700
|
$919,520 | — | 30 Jun 2023 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.29%
|
267,574
|
$428,118 | — | 30 Jun 2023 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.14%
|
125,852
|
$201,000 | — | 30 Jun 2023 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.12%
|
107,234
|
$171,574 | — | 30 Jun 2023 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.12%
|
105,809
|
$169,294 | — | 30 Jun 2023 | |
| Mill Creek Capital Advisors, LLC |
13F
|
Company |
0.11%
|
104,631
|
$167,410 | — | 30 Jun 2023 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
0.07%
|
65,628
|
$105,005 | — | 30 Jun 2023 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.04%
|
37,219
|
$59,550 | — | 30 Jun 2023 | |
| Clear Harbor Asset Management, LLC |
13F
|
Company |
0.04%
|
36,000
|
$57,600 | — | 30 Jun 2023 | |
| DIFESA CAPITAL MANAGEMENT, LP |
13F
|
Company |
0.04%
|
34,878
|
$55,805 | — | 30 Jun 2023 | |
| STATE STREET CORP |
13F
|
Company |
0.04%
|
32,907
|
$52,651 | — | 30 Jun 2023 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.03%
|
28,300
|
$45,000 | — | 30 Jun 2023 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.03%
|
26,839
|
$42,942 | — | 30 Jun 2023 | |
| SHEETS SMITH WEALTH MANAGEMENT |
13F
|
Company |
0.02%
|
20,000
|
$32,000 | — | 30 Jun 2023 | |
| Aspire Wealth Management Corp |
13F
|
Company |
0.01%
|
10,000
|
$16,000 | — | 30 Jun 2023 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
5,937
|
$9,499 | — | 30 Jun 2023 | |
| Tarek Sahmoud |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
35,000
mixed-class rows
|
$8,415 | — | 16 Aug 2022 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
1,500
|
$2,400 | — | 30 Jun 2023 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
0%
|
400
|
$640 | — | 30 Jun 2023 | |
| Retirement Group, LLC |
13F
|
Company |
0%
|
155
|
$248 | — | 30 Jun 2023 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
107
|
$171 | — | 30 Jun 2023 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
100
|
$160 | — | 30 Jun 2023 | |
| Evan G. Dick |
3/4/5
|
Former Section 16 officer |
—
class O/S missing
|
29,223
|
— | — | 15 Feb 2022 | |
| William F. Rencher |
3/4/5
|
Former Section 16 officer |
—
class O/S missing
|
8,000
|
— | — | 15 Feb 2022 |
Institutional Holders of Context Therapeutics Inc. - Common Stock (CNTX) as of Q3 2023
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2023 vs Q2 2023 Across Filers
| Investor | Q2 2023 Shares | Q3 2023 Shares | Share Diff | Share Chg % | Q2 2023 Value $ | Q3 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.